Shijiazhuang Yiling Pharmaceutical Co., Ltd.

Shijiazhuang Yiling Pharmaceutical Co., Ltd. is a National Key High-tech Enterprise listed on the Shenzhen Stock Exchange since 2011. Founded in 1992 by Mr. Wu Yiling, a member of the Chinese Academy of Engineering, Yiling specializes in the research, development, production, and sales of patented innovative Chinese herbs. The company has established a unique five-in-one operation model that integrates theory, clinical practice, research and development, industry, and education, positioning itself at the forefront of the pharmaceutical manufacturing sector. Yiling's main business lines include innovative Chinese herbs, chemical and biological medicine, and health industry products. The company has developed a robust R&D system guided by the Collateral Vessels Disease Innovation Theory, focusing on major diseases such as cardiovascular conditions, diabetes, and tumors. Yiling has received multiple patents and regulatory approvals for its products, including 12 Abbreviated New Drug Applications from the US FDA. Additionally, the company is committed to health management services, leveraging its extensive experience and resources in traditional Chinese health preservation theories combined with modern technology.

Academician Yiling Wu, lifetime honorary chairman, is a well-known Chinese medicine cardiologist and chief scientist of the Two National 973 Program. For many years, academician Yiling Wu led the team to ameliorate Collaterals Disease Theory, established the new drug R&D innovation system guided by the Collaterals Disease Theory, explore new ways to treat the major diseases guided by the Collaterals Disease Theory. A series of effective drugs have been developed for cardiovascular diseases, diabetes, tumors and avian influenza.The core competitive advantage of the company lies in the professional academic promotion mode guided by the Collateral Disease Theory. The Collateral Disease Theory is one of the core competitiveness of the company. It has a strong differentiation advantage and can greatly improve the cognition of the product. Company sales staff through its in-depth knowledge of products and professional promotion experience to carry out terminal promotion. Company's patent TCM products are new developed products guided by the Collateral Disease Theory with the exact clinical curative effect. The patented TCM products have been evaluated by the internationally recognized method of evidence-based medicine to make authoritative evaluation of their clinical curative effect, thus forming the unique advantage of academic promotion. At the same time, with the help of various academic conferences, the promotion of the characteristic advantages of patent products and the promotion of clinical doctors' recognition will lead to the rapid growth of sales.